Neuropacs Corp.'s MRI AI software earns FDA De Novo classification to assist in Parkinsonian syndrome diagnosis.
Key Details
- 1Neuropacs Corp. developed an AI-enabled MRI software targeting neurodegenerative disease evaluation.
- 2The tool differentiates between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant, and progressive supranuclear palsy.
- 3FDA has granted the product De Novo classification, indicating novel technology.
- 4The software quantifies MRI data and aids in more accurate clinical decision-making.
Why It Matters
FDA De Novo clearance validates the clinical utility of this MRI-based AI tool, potentially supporting radiologists in systematizing diagnosis of challenging neurodegenerative syndromes. This may lead to more precise patient management and sets a precedent for AI-driven neuroimaging diagnostics.
Source
Radiology Business
Related News
•AuntMinnie
Survey at SIIM Highlights Benefits and Adoption of Interactive Multimedia Reporting in Radiology
A University of Virginia survey presented at SIIM revealed radiologists have strong positive attitudes toward interactive multimedia reporting, citing efficiency and clarity gains.
•AuntMinnie
Cardiac MRI Plus AI Boosts Heart Risk Prediction Accuracy
A random-forest machine learning model leveraging cardiac MRI and patient health history improves prediction of major adverse cardiovascular events.
•Radiology Business
Subtle Medical Raises $33M for AI Imaging Workflow Expansion
Subtle Medical secured $33 million to accelerate its AI image enhancement solutions for radiology.